AIDS in Japanese Hemophiliacs by Abe Takeshi
Trop. Med., 28 (Suppl.), 77-84, December, 1986
AIDS in Japanese Hemophiliacs
77
Takeshi ABE
Department of Medicine, Teikyo University School of Medicine, Tokyo 173, Japan
AIDS is now a serious problem inJapanas has beenso
in the United States and European countries. The disease
shows a marked trend to spread rapidly over the world.
Japanese virologists, immunologists, clinicians and partici-
pants in public health have a great concern for the problem.
To date, 14 cases of AIDS have been officially acknowledged
in Japan; 7 of them were hemophiliacs. Since the first
report of AIDS in hemophiliacs in 1981 (2), they have been
recognized as being at high risk for AIDS, which is presumab-
ly due to frequent opportunities of exposure to AIDS virus,
LAV/HTLV-III (1,4,5), transmitted by blood products. Blood
products used in Japanese hemophiliacs are mostly imported
from the United States, therfore, Japanese henibhpiliacs are
similarly at high risk for AIDS.
We had two patients with AIDS developed in hemophiliacs.
Both had preceding ARC symptoms with impaired cellular immu-
nity and LAV/HTLV-III seropositivity, and then developed
fatal opportunistic infections. We present the cases in some
details here.
Patient 1 was a 48-year-old man with hemophilia B. He
had no other risk factor of AIDS. He had received factor IX
concentrates once or twice a month since 1973 when it became
available. Since the summer of 1981 he experienced repeated
fever of unknown origin and occasionally had abdominal pain
and diarrhea. Appetite loss and general malaise persisted.
He was admitted to our hospital in January and March 1982,
and was discharged both times in fairly improved conditions.
The similar symptoms recurred thereafter, and in May 1982, he
was hospitalized because of high fever with development of
generalized lymphadenopathy and erythematous skin eruptions
(Fig 1, left half). Since I had chances to see and treat
some AIDS patients in abroad beforehand, I suspected AIDS.
Although the symptoms met the criteria for AIDS proposed by
American CDC, it was difficult to make the convincing diagno-
sis. AtthattimeHTLV-III wasnotyetknownas the causa-
tive agent of AIDS.
^Episodes of fever recurred thereafter and his general
conditions grew worse progressively; he was hospitalized
again in May 1983 (Fig 1, left half). Infection with Candida
albicans occurred in the mouth and esophagus. Then he fell
into cachexia and died in June 1983, two years after the
initial fever episode.
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Fig. 1 Clinical course of Patient 1. The left half
illustrates the course of the third hospitalization and
the right half the fourth hospitalization.
The results of immunologic study of this patient is
shown in Table 1. The T4/T8 ratio, which was 0.9 in March
1983, became reduced to 0.2 in April of the same year and
remained low thereafter. The NK cell activity was extremely
depressed and PPD skin test was negative in March 1983. In
addition, the lymphocyte response to PHA and PWM was weak.
These data indicated marked impairment of cellular immunity
of the patient.
The autopsy revealed extensive candidiasis involving
various organs and outstanding atrophy of lymph nodes. Can-
dida invasion was observed even in the myocardium, which^
reflected profound impairment of the patient's immunologic
function.
Later, antibody to HTLV-III was detected in the serum,
leading to the final diagnosis of AIDS for the patient.
Patient 2 was a 62-year-old man with hemophilia A. He
had received cryoprecipitates before 1978 and factor VIII
concentrate since then when it was available for use. He
had a history of lung tuberculosis seven years before. It
was completely healed clinically and bacteriologically.
Since the summer of 1983, he gradually developed ARC symp-
toms: consisting of recurrent fever, diarrhea, malaise, and
body weight loss. He was admitted to our hospital in Septem-
ber 1983. The course of his hospitalization is shown in Fig.
2. During the hospitalization he developed lymphadenopathy
in addition to the continuation of recurrence of fever, and
diarrhea. Later, infection with Mycobacterium fortuitum
occurred, which caused troublesome cough and hemoptysis. In
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Fig. 2 Clinical course of Patient 2
in the lung. He died of respiratory insufficiency in Novem-
ber 1984, one and a half years after the onset of the ARC
symptoms.
Immunologic study showed that the T4/T8 ratio and NK
cell activity became lowered with the lapse of time since
March 1983 and PPD skin test also turned to negative (Table
2). Antibody to LAV/HTLV-III, tested in April 1983, was
positive in the serum.
The autopsy demonstrated mixed infection with atypical
mycobacteria and Aspergillus in the lung, and markedly atrop-
hied lymph nodes.













Oct Mar Apr Jun Ju l
3150 970 1850 1620 1540
34 15 ll 23
36 64 50 53
0.9 0.2 0.2 0.4
Patient 2
1983 1984
Mar Dec Mar Apr Oct
620 710 390 530 780
24 16 12 14 ll
31 55 58 58 49
0.8 0.3 0.2 0.2 0.2
1 .1 20.8 68.8 6.9 15.8
( +) (-) ( +) (+)
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By electron microscopy of the postmortem specimens,
retroviruses were observed to be present in various organs
including the lymph nodes, spleen and liver. The electron
micrographs in Fig. 3 show various stages representing the
formation of retrovirus: budding, release of virus particles,
and nucleoid maturation. This manner of virus formation is
characteristic of the retrovirus, and the mature virus,
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Fig. 3 Electron micrographs of retrovirus in the lymphnode obtained on
the necropsy of Patient 2. A-F represent various stages of the sequence
of virus formation. The bars indicate 100 nm.
To assess the blood product-associated infections of
LAV/HTLV-III and other viruses in hemophiliacs, we assayed
the sera of our patients with hemophilia for the antibodies.
Table 3 shows the results. The prevalence of seropositivity
for hepatitis B virus (HBV), Epstein-Barr virus (EBV), cyto-
megalovirus (CMV), and parvovirus (SPLV) antibodies, was
higher in hemophiliacs than in general Japanese population.
Anti-HTLV-I was positive
This rate is also high,
endemic area of adult T
III was positive in 52%
We further examined
liacs. Fig. 4 shows the
in 16 % of hemophiliacs tested,
considering that they live in non-
cell leukemia. Antibody to LAV/HTLV-
of 66 hemophiliacs.
immunologic states of our hemophi-










































Fig. 4 T4 and T8 lymphocyte counts
and T4/T8 ratios in patients with
hemophilia
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Fig. 5 Comparison of T4 and T
lymphocyte counts and T4/T8
ratio between LAV/HTLV-III sen
positive and seronegative pati
ent with hemophilia
Table 2 Prevalence of seropositivity for antibodies of
various viruses in patients with hemophilia
Antibodies No. of pati- No. of seropositive




























about a half of the patients had subnormal T4 lymphocyte
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generally increased. The T4/T8 ratios were lowered: about a
half of the patients showed the values lower than the normal
range. Other immunologic features we observed in hemophi-
liacs were that NK cell activity, lymphocyte response to
mitogens, T cell colony formation, interleukin 2 production
of T cell and delayed hypersensitivity of the skin were
suppressed; phagocytic activity of neutrophils and monocytes
was also reduced. Regarding humoral immunity, serum opsonic
activity, ASO titer and isohemagglutinin titer were lowered,
while immunoglobulin concentrations, serum immunosuppressive
acid protein (IAP) and 2~micr°9l°kulin concentrations were
elevated.
When the T lymphocyte subset data were compared between
the LAV/HTLV-III seropositive and seronegative groups, the
mean T4 lymphocyte count was lower, the mean T8 lymphocyte
count was higher, and the mean T4/T8 ratio was considerably
lower in the seropositive group than in the seronegative
group, as shown in Fig. 5. However, it was noticed that
there were patients with lowered T4 cell counts arid T4/T8
ratios in the seronegative group.
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]fig. 6 Effects of Lentinan on
T4/T8 ratios and T4 and T8 lym-
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Effects of Lentinan on neu-
trophils counts and phagocytic acti-
vity in four patients with hemophi-
lia. Neutrophil phagocytic activi-
ty was measured by chemiluminescence
response to stimulation with opso-
nized zymosan
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Treatment of AIDS is a much more dificult problem at
present. In spite of great efforts, definitely effective
means of therapy have not been established yet. Approaches
to this problem should be made in three directtions: 1. kill-
ing of the causative virus, LAV/HTLV-III, 2. augmentation of
immunologic functions, 3. therapy for opportunistic infec-
tions. A number of agents have thus far been proposed and
tried for possible effect to improve immunologic dysfunctions
of AIDS and ARC patients. We are trying a few drugs to
hemophilic patients with LAV/HTLV-III seropositivity and
lowered T4/T8 ratio. Here we report a trial of Lentinan, a
polysaccharide immuno-modulating agent (3), in four hemophi-
liacs. Lentinan was given at a dose of 10 mg once every
week, and the changes in T4 and T8 lymphocyte counts, T4/T8
ratio, and neutrophil phagocytic activity were followed.
As shown in Fig. 6, the T4 counts increased in three patients
and the T4/T8 ratio rose in one patient. Noticeably, phago-
cytic activity of neutrophils, as measured by chemilumines-
cence, increased to almost normal range in all the four
patients treated. These effects may contribute favorably to
host defence in the patients with defect of cellular immunity
and hopefully prevent development of AIDS. Of course, much
more clinical studies on this and other drugs are required
for evaluation.
Finally, I express my annoying but sincere questions in
dealing with hemophiliacs at risk for AIDS in consideration
from not only medical but also social and psycological as-
pects. Firstly, how to promote the survey of LAV/HTLV-III
infection in the hemophilacs? Secondly, how to deal with the
results of the tests? Particularly, whether the results
shouldbe informed tothe patients ornot? Can wedoitto
seropositive patients without getting up a panic among them
at the present time we have no definite therapeutic means
against AIDS? Thirdly, how to guide the patients to behave
themselves at home and society to avoid further spread of
LAV/HTLV-III virus from them.
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